Log in

NASDAQ:PODDInsulet Stock Price, Forecast & News

$188.78
+0.21 (+0.11 %)
(As of 06/1/2020 04:00 PM ET)
Add
Compare
Today's Range
$185.00
Now: $188.78
$190.80
50-Day Range
$178.43
MA: $198.50
$224.73
52-Week Range
$107.83
Now: $188.78
$228.79
Volume370,732 shs
Average Volume630,716 shs
Market Capitalization$11.91 billion
P/E Ratio2,360.05
Dividend YieldN/A
Beta0.89
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod. It sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, Israel, and internationally. Insulet Corporation was founded in 2000 and is headquartered in Acton, Massachusetts.
Read More
Insulet logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.2Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.36 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:PODD
CUSIP45784P10
Phone978-600-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$738.20 million
Cash Flow$0.64 per share
Book Value$1.23 per share

Profitability

Net Income$11.60 million

Miscellaneous

Employees1,350
Market Cap$11.91 billion
Next Earnings Date8/3/2020 (Estimated)
OptionableOptionable

Receive PODD News and Ratings via Email

Sign-up to receive the latest news and ratings for PODD and its competitors with MarketBeat's FREE daily newsletter.

Insulet (NASDAQ:PODD) Frequently Asked Questions

How has Insulet's stock been impacted by COVID-19 (Coronavirus)?

Insulet's stock was trading at $172.11 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PODD stock has increased by 9.7% and is now trading at $188.78. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Insulet?

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 1 sell rating, 10 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Insulet.

When is Insulet's next earnings date?

Insulet is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Insulet.

How were Insulet's earnings last quarter?

Insulet Co. (NASDAQ:PODD) announced its quarterly earnings data on Thursday, May, 7th. The medical instruments supplier reported ($0.03) EPS for the quarter, missing the Zacks' consensus estimate of ($0.02) by $0.01. The medical instruments supplier had revenue of $198 million for the quarter, compared to analyst estimates of $189.61 million. Insulet had a net margin of 0.66% and a return on equity of 7.66%. The business's quarterly revenue was up 23.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.07 earnings per share. View Insulet's earnings history.

What guidance has Insulet issued on next quarter's earnings?

Insulet issued an update on its second quarter 2020 After-Hours earnings guidance on Thursday, May, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $210.792-217.877 million, compared to the consensus revenue estimate of $201.99 million.

What price target have analysts set for PODD?

20 brokerages have issued twelve-month price targets for Insulet's stock. Their forecasts range from $100.00 to $250.00. On average, they anticipate Insulet's share price to reach $189.00 in the next year. This suggests a possible upside of 0.1% from the stock's current price. View analysts' price targets for Insulet.

Has Insulet been receiving favorable news coverage?

Media coverage about PODD stock has been trending very positive recently, according to InfoTrie. The research group ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Insulet earned a coverage optimism score of 3.5 on InfoTrie's scale. They also gave news coverage about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutInsulet.

Who are some of Insulet's key competitors?

What other stocks do shareholders of Insulet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include DexCom (DXCM), NVIDIA (NVDA), Alibaba Group (BABA), Netflix (NFLX), Veeva Systems (VEEV), Adobe (ADBE), salesforce.com (CRM), Shopify (SHOP), Teladoc Health (TDOC) and Alteryx (AYX).

Who are Insulet's key executives?

Insulet's management team includes the following people:
  • Ms. Shacey Petrovic, Pres, CEO & Director (Age 45)
  • Mr. Charles Alpuche, Exec. VP & COO (Age 59)
  • Mr. Bret Christensen, Exec. VP & Chief Commercial Officer (Age 47)
  • Mr. Patrick J. Sullivan, Consultant (Age 67)
  • Mr. Michael L. Levitz, Advisor (Age 45)

What is Insulet's stock symbol?

Insulet trades on the NASDAQ under the ticker symbol "PODD."

Who are Insulet's major shareholders?

Insulet's stock is owned by a number of institutional and retail investors. Top institutional investors include Capital Research Global Investors (10.96%), Capital World Investors (8.63%), Wellington Management Group LLP (4.27%), Primecap Management Co. CA (3.34%), Clearbridge Investments LLC (2.45%) and Fred Alger Management LLC (2.10%). Company insiders that own Insulet stock include Aiman Abdel-Malek, Charles Alpuche, Corinne H Nevinny, David A Lemoine, David Colleran, John A Fallon, Michael L Levitz, Michael P Spears, Sally Crawford and Shacey Petrovic. View institutional ownership trends for Insulet.

Which institutional investors are selling Insulet stock?

PODD stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Primecap Management Co. CA, William Blair Investment Management LLC, Lord Abbett & CO. LLC, Invesco Ltd., Federated Hermes Inc., Fred Alger Management LLC, and Waddell & Reed Financial Inc.. Company insiders that have sold Insulet company stock in the last year include Corinne H Nevinny, David A Lemoine, John A Fallon, Michael P Spears, and Shacey Petrovic. View insider buying and selling activity for Insulet.

Which institutional investors are buying Insulet stock?

PODD stock was acquired by a variety of institutional investors in the last quarter, including Capital World Investors, Carillon Tower Advisers Inc., Fisher Asset Management LLC, Capital Research Global Investors, Wellington Management Group LLP, Scout Investments Inc., Sumitomo Mitsui Trust Holdings Inc., and Perceptive Advisors LLC. View insider buying and selling activity for Insulet.

How do I buy shares of Insulet?

Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Insulet's stock price today?

One share of PODD stock can currently be purchased for approximately $188.78.

How big of a company is Insulet?

Insulet has a market capitalization of $11.91 billion and generates $738.20 million in revenue each year. The medical instruments supplier earns $11.60 million in net income (profit) each year or $0.19 on an earnings per share basis. Insulet employs 1,350 workers across the globe.

What is Insulet's official website?

The official website for Insulet is www.insulet.com.

How can I contact Insulet?

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The medical instruments supplier can be reached via phone at 978-600-7000 or via email at [email protected]

This page was last updated on 6/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.